Chemours Co (CC) Given Consensus Recommendation of “Hold” by Analysts

Chemours Co (NYSE:CC) has been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $56.50.

A number of research analysts recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Chemours from $48.00 to $47.00 and set a “hold” rating on the stock in a research report on Tuesday, September 25th. Barclays restated a “buy” rating and set a $62.00 price objective on shares of Chemours in a report on Tuesday, August 7th. BMO Capital Markets lowered their price objective on shares of Chemours from $70.00 to $68.00 and set an “outperform” rating on the stock in a report on Monday, August 6th. ValuEngine downgraded shares of Chemours from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 15th. Finally, Citigroup lowered their price objective on shares of Chemours from $69.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, July 11th.

Chemours stock opened at $32.41 on Tuesday. The company has a debt-to-equity ratio of 3.86, a quick ratio of 1.47 and a current ratio of 2.09. Chemours has a 12-month low of $31.34 and a 12-month high of $57.68. The firm has a market cap of $5.88 billion, a P/E ratio of 8.48, a P/E/G ratio of 0.38 and a beta of 2.75.



Chemours (NYSE:CC) last released its earnings results on Thursday, August 2nd. The specialty chemicals company reported $1.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.18. Chemours had a net margin of 15.11% and a return on equity of 107.22%. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.82 billion. During the same quarter in the previous year, the company earned $0.87 EPS. Chemours’s quarterly revenue was up 14.4% compared to the same quarter last year. On average, equities research analysts expect that Chemours will post 5.7 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Alambic Investment Management L.P. purchased a new stake in shares of Chemours in the second quarter valued at about $519,000. Systematic Financial Management LP purchased a new stake in shares of Chemours in the second quarter valued at about $1,298,000. Cozad Asset Management Inc. purchased a new stake in shares of Chemours in the second quarter valued at about $276,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Chemours in the second quarter valued at about $247,000. Finally, Korea Investment CORP raised its holdings in shares of Chemours by 16.5% in the second quarter. Korea Investment CORP now owns 357,655 shares of the specialty chemicals company’s stock valued at $15,866,000 after purchasing an additional 50,700 shares during the last quarter. Institutional investors own 76.59% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: Growth Stocks, What They Are, What They Are Not

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply